Trial reportClinical ophthalmology (Auckland, N.Z.)2026
Clinical Performance After Implantation of a New Purely Refractive Extended Depth of Field Intraocular Lens in Cataract Patients.
Trial report in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the functional outcomes including visual performance and patient reported outcomes after implantation of a refractive Extended Depth of Field (EDoF) intraocular lens (IOL) in a post-approval prospective, non-controlled study. Patients and Methods: Fifty-eight eyes of 29 patients (mean age: 71 ± 11 years) that underwent phacoemulsification cataract surgery with implantation of a DEN00V or DET100-600 IOL (TECNIS PureSee, Johnson & Johnson Vision Inc. Jacksonville, Florida, USA) were included in this prospective study. Postoperative follow-up at 3 months included uncorrected and corrected distance visual acuity (UDVA/CDVA), uncorrected and distance corrected intermediate visual acuity at 80 cm (UIVA/DCIVA), and uncorrected and distance corrected near visual acuity at 40 cm (UNVA/ DCNVA), as well as binocular corrected defocus curve analysis (range +2 to -4 dioptres), contrast sensitivity under photopic and mesopic conditions (CSV-1000, VectorVision, Greenville, USA) and patient-reported outcome (Heidelberg Daily Task Evaluation (DATE) Questionnaire and halo and glare evaluation). Results: Mean binocular visual acuity in logMAR at 3 months was UDVA/ CDVA (-0.02/ -0.07), UIVA/ DCIVA (0.03/ 0.02) and UNVA/ DCNVA (0.16/ 0.16). The defocus curve analysis showed a visual acuity of 0.20 logMAR or better up to -2.25 D. Contrast sensitivity under photopic and mesopic conditions was within normal age limits. The study IOL was non-inferior to standard monofocal lenses in terms of halo/glare. Eighty-three percent of participants were fully satisfied with the outcome of the IOL implantation and ninty-six percent of patients would repeat the surgery with the same IOL and recommend the IOL to friends or acquaintances. Conclusion: The TECNIS PureSee IOL yielded good visual performance with high patient satisfaction. Patients received a good EDoF-effect with a low probability of disturbing photopic phenomena in terms of halo and glare.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.